Medical Condition News

RSS

Lower extremity injuries on the rise among skiers

Over the last two decades, knee injuries have been on the rise among skiers in the French Alps. It is more likely for downhill skiers to experience a lower extremity injury than any other type of injury, whether due to a fall or a collision.

20 Oct 2009

Right combination of estrogen and SERM can reduce breast cancer risk

The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21.

20 Oct 2009

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in Montreal, Quebec, making Canada one of the first countries worldwide to launch this state-of-the-art pen.

20 Oct 2009

Internet training could potentially enhance brain function and cognition in older adults: Study

You can teach an old dog new tricks, say UCLA scientists who found that middle-aged and older adults with little Internet experience were able to trigger key centers in the brain that control decision-making and complex reasoning after just one week of surfing the Web.

20 Oct 2009

Therapists can help individuals to cope with mental health issues

As more Californians experience “Furlough Friday,” voluntary pay cuts and forced retirement, the California Association of Marriage and Family Therapists (CAMFT) encourages you to find a therapist to cope with the mental health impact of the economic downturn.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

Online training program to address the needs of autistic individuals

Continuing to be at the forefront of innovative research, education and services for individuals with developmental disabilities such as autism, the Training, Education and Research Institute (TERI), Inc. today launched a first-of-its-kind, comprehensive online training program aimed at creating a pool of Life Coaches to assist this special population and their families.

20 Oct 2009

UT student receives fellowship grant for pre-eclampsia research

Roxanna Irani, a M.D./Ph.D. student at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), has received a $10,000 fellowship for her efforts to better understand a condition known as pre-eclampsia that threatens the lives of expectant women and their unborn children.

20 Oct 2009

New technique to treat metabolic disorders in babies while still in the womb

Researchers say a new development in cord blood transplants for inherited metabolic disorders may be curative for some babies who are treated while still in the womb.

20 Oct 2009

Health Canada issues Notice of Non-Compliance to Winston Laboratories for CIVANEX

Winston Laboratories, Inc. (“Winston Labs”), a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced that it has received a Notice of Non-compliance (“NON”) from the Therapeutics Drug Directorate, Health Canada (the “Directorate”) for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Oct 2009

Multilingual capability has a positive impact on cognitive functions

For a considerable time already there has been discussion within scientific circles about whether knowing and using multiple languages could possibly have positive effects on the human brain and thinking. There have been a number of international studies on the subject, which indicate that the ability to use more than one language brings an individual a considerable advantage.

20 Oct 2009

Diabetes represents a global health threat

The International Diabetes Federation (IDF) released new data today showing that a staggering 285 million people worldwide have diabetes.

20 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

20 Oct 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009